Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Recruiting N/A Interventional Study
Multiple Myeloma in Relapse Multiple Myeloma, Refractory Multiple Myeloma Stage III Multiple Myeloma Progression Multiple Myeloma B Cell Lymphoma Lymphoma, B-Cell Aggressive Lymphoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Supportive Care
Participants needed
144 (estimated)
Sponsor
University Health Network, Toronto · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual can…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Patient eligibility criteria: Inclusion criteria: (i) Age ≥18 years; (ii) A new diagnosis of multiple myeloma or at progression of disease necessitating a change in treatment plan, or relapsed/refractory aggressive B cell lymphoma after one prior line of therapy; (iii) Eastern Cooperative Oncology…
Contacts

Breffni Hannon, MB BCh BAO, MMedSci, MCFP

416-946-4501

Breffni.Hannon@uhn.ca

CONTACT